Jennifer Lynn Short
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Jennifer Lynn Short has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
- Andrew John Lawrence
Florey Institute of Neuroscience and Mental Health Parkville Victoria Australia
1 shared publication Annie X. Zeng
Australian Centre for Research on Separation Science, School of Chemistry, Monash University, Clayton, Victoria 3800, Australia
1 shared publicationC. Ledent
Institut de Recherche Interdisciplinaire, Faculté de Médecine, Université de Bruxelles, Brussels, Belgium
1 shared publication- Christopher J. H. Porter
Drug Delivery, Disposition and Dynamics, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, VIC, Australia
1 shared publication E. Borrelli
Department of Neurobiology, Institut de Génétique et de Biologie Moléculaire et Cellulaire, Universite de Strasbourg, Illkirch Cedex, France
1 shared publicationJ. Drago
Brain Injury and Repair Group, Howard Florey Institute, University of Melbourne, Royal Parade, Parkville, Victoria 3010, Australia
1 shared publication
Latest Publications
- Open Access
- 16 November 2016
- Published by Society for Neuroscience in Journal of Neuroscience
- Vol. 36 (46) , 11755-11767
Fatty Acid-Binding Protein 5 at the Blood–Brain Barrier Regulates Endogenous Brain Docosahexaenoic Acid Levels and Cognitive Function
Fatty acid-binding protein 5 (FABP5) at the blood–brain barrier contributes to the brain uptake of docosahexaenoic acid (DHA), a blood-derived polyunsaturated fatty acid essential for maintenance of cognitive function. Given the importance of DHA in cognition, the aim of this study was to investigate whether deletion of FABP5 results in cognitive dysfunction and whether this is associated with reduced brain endothelial cell uptake of exogenous DHA and subsequent attenuation in the brain levels of endogenous DHA. Cognitive function was assessed in male and female FABP5+/+and FABP5−/−mice using a battery of memory paradigms. FABP5−/−mice exhibited impaired working memory and short-term memory, and these cognitive deficits were associated with a 14.7 ± 5.7% reduction in endogenous brain DHA levels. The role of FABP5 in the blood–brain barrier transport of DHA was assessed by measuring14C-DHA uptake into brain endothelial cells and capillaries isolated from FABP5+/+and FABP5−/−mice. In line with a crucial role of FABP5 in the brain uptake of DHA,14C-DHA uptake into brain endothelial cells and brain capillaries of FABP5−/−mice was reduced by 48.4 ± 14.5% and 14.0 ± 4.2%, respectively, relative to those of FABP5+/+mice. These results strongly support the hypothesis that FABP5 is essential for maintaining brain endothelial cell uptake of DHA, and that cognitive deficits observed in FABP5−/−mice are associated with reduced CNS access of DHA.SIGNIFICANCE STATEMENTGenetic deletion of fatty acid-binding protein 5 (FABP5) in mice reduces uptake of exogenous docosahexaenoic acid (DHA) into brain endothelial cells and brain capillaries and reduces brain parenchymal levels of endogenous DHA. Therefore, FABP5 in the brain endothelial cell is a crucial contributor to the brain levels of DHA. Critically, lowered brain DHA levels in FABP5−/−mice occurred in tandem with cognitive deficits in a battery of memory paradigms. This study provides evidence of a critical role for FABP5 in the maintenance of cognitive function via regulating the brain uptake of DHA, and suggests that upregulation of FABP5 in neurodegenerative diseases, where brain DHA levels are possibly diminished (e.g., Alzheimer's disease), may provide a novel therapeutic approach for restoring cognitive function.
- 16 November 2016
- Published by Society for Neuroscience in Journal of Neuroscience
- Vol. 36 (46) , 11755-11767
Open AccessFatty Acid-Binding Protein 5 at the Blood–Brain Barrier Regulates Endogenous Brain Docosahexaenoic Acid Levels and Cognitive Function
Fatty acid-binding protein 5 (FABP5) at the blood–brain barrier contributes to the brain uptake of docosahexaenoic acid (DHA), a blood-derived polyunsaturated fatty acid essential for maintenance of cognitive function. Given the importance of DHA in cognition, the aim of this study was to investigate whether deletion of FABP5 results in cognitive dysfunction and whether this is associated with reduced brain endothelial cell uptake of exogenous DHA and subsequent attenuation in the brain levels of endogenous DHA. Cognitive function was assessed in male and female FABP5+/+and FABP5−/−mice using a battery of memory paradigms. FABP5−/−mice exhibited impaired working memory and short-term memory, and these cognitive deficits were associated with a 14.7 ± 5.7% reduction in endogenous brain DHA levels. The role of FABP5 in the blood–brain barrier transport of DHA was assessed by measuring14C-DHA uptake into brain endothelial cells and capillaries isolated from FABP5+/+and FABP5−/−mice. In line with a crucial role of FABP5 in the brain uptake of DHA,14C-DHA uptake into brain endothelial cells and brain capillaries of FABP5−/−mice was reduced by 48.4 ± 14.5% and 14.0 ± 4.2%, respectively, relative to those of FABP5+/+mice. These results strongly support the hypothesis that FABP5 is essential for maintaining brain endothelial cell uptake of DHA, and that cognitive deficits observed in FABP5−/−mice are associated with reduced CNS access of DHA.SIGNIFICANCE STATEMENTGenetic deletion of fatty acid-binding protein 5 (FABP5) in mice reduces uptake of exogenous docosahexaenoic acid (DHA) into brain endothelial cells and brain capillaries and reduces brain parenchymal levels of endogenous DHA. Therefore, FABP5 in the brain endothelial cell is a crucial contributor to the brain levels of DHA. Critically, lowered brain DHA levels in FABP5−/−mice occurred in tandem with cognitive deficits in a battery of memory paradigms. This study provides evidence of a critical role for FABP5 in the maintenance of cognitive function via regulating the brain uptake of DHA, and suggests that upregulation of FABP5 in neurodegenerative diseases, where brain DHA levels are possibly diminished (e.g., Alzheimer's disease), may provide a novel therapeutic approach for restoring cognitive function.
- Open Access
- 1 September 2006
- Published by Elsevier in The Journal of Pharmacology and Experimental Therapeutics
- Vol. 318 (3) , 1171-1177
Intravenous Insulin-like Growth Factor-I Receptor Antisense Treatment Reduces Angiotensin Receptor Expression and Function in Spontaneously Hypertensive Rats
The present study investigated the effects of a functional deficit in insulin-like growth factor-I signaling via chronic intravenous administration of insulin-like growth factor-I (IGF-I) receptor antisense in the conscious spontaneously hypertensive rat cardiovascular system. Insulin-like growth factor-I receptor (IGF-IR) antisense, but not full mismatch treatment, decreased IGF-IR expression in both conductance and resistance blood vessels. Aortic IGF-IR density was reduced by 67.4 ± 6.0% in antisense-treated spontaneously hypertensive rat (SHR) compared with untreated animals, whereas mismatch treatment had no effect (analysis of variance, n = 3, P < 0.01). Aortic and tail artery angiotensin II type 1 receptor expression was significantly reduced by IGF-IR antisense treatment, whereas angiotensin II type 2 receptor expression was unaffected by administration of antisense and mismatch oligonucleotides. IGF-I receptor antisense treatment caused a significant decrease in pressor responses to angiotensin II in comparison with full-length mismatch treatment (Emax was reduced to 65 ± 7 mm Hg compared with 99 ± 6 mm Hg, p < 0.05). Likewise, a reduction in pressor responses to noradrenaline was observed in hypertensive rats treated with IGF-IR antisense compared with full mismatch-treated rats (Emax was reduced to 60 ± 6 mm Hg compared with 108 ± 5 mm Hg, p < 0.01). There was no clear antisense effect on resting blood pressure and no effect at on aortic medial thickness. These results suggest that although the proliferative and vasodilator effects of IGF-I are impaired in SHR, the effects on angiotensin receptor expression remain profound.
- 1 September 2006
- Published by Elsevier in The Journal of Pharmacology and Experimental Therapeutics
- Vol. 318 (3) , 1171-1177
Open AccessIntravenous Insulin-like Growth Factor-I Receptor Antisense Treatment Reduces Angiotensin Receptor Expression and Function in Spontaneously Hypertensive Rats
The present study investigated the effects of a functional deficit in insulin-like growth factor-I signaling via chronic intravenous administration of insulin-like growth factor-I (IGF-I) receptor antisense in the conscious spontaneously hypertensive rat cardiovascular system. Insulin-like growth factor-I receptor (IGF-IR) antisense, but not full mismatch treatment, decreased IGF-IR expression in both conductance and resistance blood vessels. Aortic IGF-IR density was reduced by 67.4 ± 6.0% in antisense-treated spontaneously hypertensive rat (SHR) compared with untreated animals, whereas mismatch treatment had no effect (analysis of variance, n = 3, P < 0.01). Aortic and tail artery angiotensin II type 1 receptor expression was significantly reduced by IGF-IR antisense treatment, whereas angiotensin II type 2 receptor expression was unaffected by administration of antisense and mismatch oligonucleotides. IGF-I receptor antisense treatment caused a significant decrease in pressor responses to angiotensin II in comparison with full-length mismatch treatment (Emax was reduced to 65 ± 7 mm Hg compared with 99 ± 6 mm Hg, p < 0.05). Likewise, a reduction in pressor responses to noradrenaline was observed in hypertensive rats treated with IGF-IR antisense compared with full mismatch-treated rats (Emax was reduced to 60 ± 6 mm Hg compared with 108 ± 5 mm Hg, p < 0.01). There was no clear antisense effect on resting blood pressure and no effect at on aortic medial thickness. These results suggest that although the proliferative and vasodilator effects of IGF-I are impaired in SHR, the effects on angiotensin receptor expression remain profound.
- 1 January 2006
- Published by Elsevier in Neuroscience
- Vol. 139 (2) , 661-670
Genetic interdependence of adenosine and dopamine receptors: Evidence from receptor knockout mice
- 1 January 2006
- Published by Elsevier in Neuroscience
- Vol. 139 (2) , 661-670
Genetic interdependence of adenosine and dopamine receptors: Evidence from receptor knockout mice